SCHEMBL12165745

SCHEMBL12165745

CC(=O)Cc1ccccc1Cn1nc2c(N)nc3ccccc3n2c1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 14/20 0.50
▸ ADORA2A P29274 9/20 0.50
▸ ADORA1 P30542 6/20 0.50
▸ KDM4E B2RXH2 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CASP1 P29466 2/20 0.39
▸ CASP7 P55210 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ KEAP1 Q14145 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16065954 0.88 ADORA3 (0.55) ADORA3ADORA2AADORA1KDM4EMEN1
SCHEMBL12165501 0.86 ADORA3 (0.54) ADORA3ADORA2AADORA1
SCHEMBL12165570 0.85 ADORA3 (0.48) ADORA3ADORA2AADORA1POLB
SCHEMBL12165529 0.84 ADORA3 (0.56) ADORA3ADORA2AADORA1NPC1RAB9A
SCHEMBL12165502 0.84 ADORA3 (0.56) ADORA3ADORA2AADORA1
SCHEMBL12165767 0.83 ADORA3 (0.54) ADORA3ADORA2AADORA1KDM4ECASP1
SCHEMBL14922233 0.82 ADORA3 (0.52) ADORA3ADORA2AADORA1
SCHEMBL12165586 0.82 ADORA3 (0.47) ADORA3ADORA2AADORA1KDM4EALDH1A1
SCHEMBL12165723 0.82 ADORA3 (0.49) ADORA3ADORA2AADORA1KDM4ECASP1
SCHEMBL16065952 0.82 ADORA3 (0.56) ADORA3ADORA2AADORA1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — US disclosed
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY ADORA2A, ADORA3, ADORA1 ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback